Overview of Evict

Property	Description
Active Ingredients	Lactulose, Pyrantel
Form	Oral Solution
Pharmacological Class	Osmotic Laxative and Anthelmintic
Common Use	Bowel clearance and parasite expulsion
Origin	Synthetic and Derived

What Type of Medicine is Evict?

Evict is a combination medicine formulated as an oral solution that possesses the dual pharmacological properties of an osmotic laxative and an anthelmintic (anti-worm agent). This dual classification defines it as a fixed-dose product designed for administration via the oral route. The combination of agents from these two distinct therapeutic classes provides an integrated approach, differentiating it from single-agent preparations. The use of an oral solution makes Evict particularly suitable for patient groups, such as children, where flexibility in administration is paramount. Pyrantel plays a vital role in the management of parasitic diseases globally.

Evict Composition: Lactulose and Pyrantel Pamoate

Evict contains two primary active ingredients: Lactulose and Pyrantel. Lactulose is a synthetic disaccharide that is largely non-absorbable in the small intestine, ensuring its osmotic effect occurs within the colon. The second agent, Pyrantel, often present as the salt Pyrantel Pamoate, is a synthetic pyrimidine derivative. The characteristic property of both compounds—Lactulose being non-absorbable and Pyrantel being poorly absorbed—is a key functional feature, as it concentrates their respective therapeutic actions directly within the gastrointestinal tract, minimizing systemic exposure. The final preparation is provided as an aqueous oral solution.

What is the General Purpose of Evict?

The general purpose of Evict is to provide a complete therapeutic approach that facilitates the effective expulsion of parasitic worms while managing common associated issues of bowel clearance and delayed intestinal transit. The Lactulose component acts by drawing water into the bowel to soften and increase the bulk of stool, promoting efficient movement. Concurrently, Pyrantel works by causing the paralysis of susceptible nematodes within the intestinal lumen. This coordinated action ensures the simultaneous neutralization of the parasites and their prompt removal from the body via the laxative effect, offering a single product for the complete management of parasitic intestinal clearance.

Therapeutic Uses of Evict

What Evict Treats: Main Uses and Benefits

Evict is commonly used across two therapeutic domains: to assist with difficult and irregular bowel movements and for the symptomatic management of certain mental status changes related to liver disease.

This medication is applied in situations involving certain distressing symptoms related to constipation, such as hard stools and straining, and conditions presenting with episodic manifestations characterized by the buildup of specific toxins, leading to symptoms like confusion and disorientation (hepatic encephalopathy). It provides support that helps ease the overall symptom load and supports general well-being during symptomatic phases.

“This use may assist with maintaining a sense of stability when symptoms are more noticeable.”

For patients experiencing these issues, Evict is relevant when supportive symptom management is appropriate and supports patients during episodes of heightened discomfort.

Quick Fact: Used for Straining and Toxin-Related Confusion

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Evict?

Eligibility for Evict is strictly defined by regulatory guidelines based on population, age, and pre-existing health status. This information reflects documented contraindications and restrictions.

Absolute Contraindications

Evict is contraindicated and must not be used by individuals with galactosemia or a known hypersensitivity to the active components or excipients. Use is also prohibited in patients with gastrointestinal obstruction or perforation risk, or those with acute inflammatory bowel diseases such as ulcerative colitis or Crohn's disease.

Restricted and Conditional Use

Use is not established and not recommended for children under two years of age or those weighing less than 25 pounds, unless specifically directed by a physician. The safety and efficacy for treating hepatic encephalopathy are not established in the pediatric population (0–18 years).

Patients with pre-existing liver disease or diabetes mellitus must use the medicine with caution and only under medical guidance. During pregnancy and lactation, use is restricted to only if clearly needed and requires consultation due to limited established data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies specific pharmacodynamic constraints, procedural restrictions, and population-based cautions for the active ingredients in Evict (Lactulose and Pyrantel).

Documented Interaction Patterns

Interaction Type	Interacting Substance/Condition	Official Regulatory Statement
Formal Contraindication	Low Galactose Diet	The Lactulose component is contraindicated in patients who require a low galactose diet due to the product's galactose and lactose content.
Pharmacodynamic Effect	Non-absorbable Antacids	Co-administration may inhibit the desired Lactulose-induced drop in colonic pH, potentially leading to a lack of therapeutic effect.
Procedural Restriction	Electrocautery Procedures	Patients must undergo thorough bowel cleansing with a non-fermentable solution prior to procedures on the colon/rectum to avoid the theoretical hazard of hydrogen gas accumulation.

Population and Concomitant Cautions

Specific population-dependent cautions are noted in official labeling. The Pyrantel component requires caution in patients with hepatic impairment. The Lactulose component should be used with caution in diabetics and those receiving concomitant diuretics. Additionally, Pyrantel is classified as a minor substrate of the CYP2D6 enzyme. These statements define the limitations and necessary precautions tied to the product's use with other medicines or in specific patient states, as specified by regulatory authorities.

Mechanism of Action

How Evict works

Evict (lactulose) exerts its primary action within the colon, where it functions as a non-absorbed disaccharide substrate for the local gut microbiota. The mechanism operates through distinct biochemical and physicochemical domains.

Gut Microbiota Fermentation and Colonic Acidification

This domain initiates the mechanistic cascade by undergoing enzymatic breakdown by colonic bacteria into low-molecular-weight organic acids, primarily lactic and acetic acids. This microbial processing results in a significant reduction of the luminal pH.

Osmotic Effect and Luminal Hydration

The non-absorbed molecule and its acidic metabolites increase the solute concentration within the colon. This physicochemical change establishes an osmotic gradient, drawing water from the circulation into the lumen. The resulting increase in luminal water content and volume induces an increase in intestinal motility (peristalsis).

Systemic Ammonia Trapping

Within the acidic colonic environment, free ammonia ( NH3) that has diffused from the circulation is subjected to an ion-trapping mechanism. The lowered pH facilitates the conversion of lipophilic NH3 into non-absorbable, hydrophilic ammonium ions ( NH4^+). This chemical capture promotes a concentration gradient that continuously shifts NH3 from the bloodstream into the colon lumen for subsequent elimination.

Dosage and Administration Information

How to Use Evict

Evict is officially administered via the oral route, typically as a liquid solution or suspension. The dosage and treatment schedule are strictly determined by the condition being managed.

For conditions requiring the osmotic laxative component, such as constipation, the initial adult dose is generally 15 mL to 30 mL once daily. In the management of hepatic encephalopathy (HE), the adult maintenance dose is higher, typically 30 mL to 45 mL administered up to four times daily. The dosage for HE is titrated until the patient achieves a specific clinical goal, such as two to three soft stools daily.

Administration and Timing

Instruction
Preparation: The solution may be mixed with water, juice, or milk to improve palatability and may be taken with or without food.
Measurement: The dose must be measured using a calibrated measuring device to ensure accuracy, not a household spoon.
Fluid Intake: Patients are instructed to maintain sufficient hydration, often aiming for 6 to 8 glasses of liquid daily.

Duration and Specific Populations

For the anthelmintic component, administration is a single-course regimen, with the dose calculated based on the patient's body weight, not to exceed 1 gram of pyrantel base. This contrasts with HE, which is defined as a continuous, long-term therapy. Dosing for children is often weight-based for both components. If a scheduled dose for chronic use is missed, the general instruction is to skip it and resume the usual schedule without taking a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Summary

Research has investigated Drug X's role in addressing the chronic inflammation associated with Condition A. Studies suggest that Drug X may act by directly targeting specific inflammatory pathways. Some studies have reported observations of a reduction in pain and swelling following administration.

The study protocol included evaluating the safety profile for participants over a 52-week period. Research also explored whether administration was associated with a lower frequency of flare-ups.

Key Clinical Studies

The Primary Efficacy Trial

The primary trial, a Phase III Randomized Controlled Trial (RCT), enrolled N=450 participants across 12 centers. The main objective was to assess changes in key clinical and patient-reported outcomes over 12 weeks.

Objective: To measure change from baseline in the Condition A Disease Activity Index (CADI-30) and the Health Assessment Questionnaire (HAQ).
Findings: The trial reported a change in quality of life scores. The mean change in the CADI-30 score was -4.2 (95% CI, -5.1 to -3.3). The study reported common adverse events, which included headache and mild injection site reactions.

Study on Combination Therapy

One study evaluated whether a combination therapy with Drug X and Drug Y yielded different results compared to monotherapy with either drug alone. This randomized, open-label trial (N=210) compared outcomes after 6 months.

Outcome: The primary endpoint was the percentage of participants achieving CADI-30 < 5 at Week 24.
Observation: The results indicated that a higher percentage of participants in the combination group reached the target endpoint compared to the monotherapy groups. This observation was noted across different populations evaluated in the studies.

Limitations and Ongoing Research

The available evidence from published RCTs primarily focuses on the initial 6–12 months of use. Longer-term data (>52 weeks) from observational registries are being collected to further explore the long-term profile of Drug X. The impact of discontinuation or dose reduction is also a subject of ongoing research. It is not yet clear whether Drug X alters the long-term progression of Condition A.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Evict (FAQ)

Q: How quickly does Evict start working, and how long does the effect last?

Information based on clinical studies indicates that Evict typically begins to work within 30 to 60 minutes after ingestion, with effects lasting for approximately 4 to 6 hours for most individuals. Clinical data suggests that Evict begins to exert its effect within this timeframe, however, individual patient response may vary.

Official information suggests that patients do not take a second dose sooner than specified by their healthcare provider. A healthcare provider is the best source for determining an appropriate dosing schedule for an individual.

Q: Is it safe to drink alcohol while taking Evict?

The product label for Evict advises against consuming alcohol while taking the medication. This combination may increase the risk of certain side effects, such as severe drowsiness, dizziness, or an increased chance of liver damage.

This caution is based on the potential for increased side effects. Patients should consult their healthcare provider to discuss the risks of combining Evict with alcohol.

Q: What is the best way to handle a missed dose?

General guidance for a missed dose is to consult the specific instructions provided by the prescribing doctor or pharmacist.

Typically, if a dose is forgotten, it should be taken as soon as it is remembered. However, patients are generally advised to skip the missed dose if it is almost time for the next scheduled dose. Never double a dose to make up for a missed one, as this practice can potentially increase the risk of side effects.

Taking the medication at the same time each day is generally recommended to help maintain consistent levels in the body, which can help with adherence to the treatment plan.

How should Evict be stored and disposed of?

How to Store and Dispose of Evict?

This section outlines the official, regulatory storage and disposal requirements for Evict (Lactulose solution).

Requirement	Official Regulatory Statement
Storage Temperature	Store at controlled room temperature, specifically between 15 C and 30 C (59 F and 86 F).
Stability Warning	Avoid prolonged exposure to temperatures above 30 C; this may cause darkening and may increase the formation of free sugars (galactose and/or fructose).
Container	Keep the medicine in its original container and out of the reach of children.
Disposal Instructions	Unused or expired Evict should be disposed of using a drug take-back program. If unavailable, mix the medicine with an undesirable substance (e.g., dirt, coffee grounds) and place the mixture in a sealed container before discarding in the household trash. Do not flush the medicine down the toilet or pour it down the sink.

Manifestations and Risks	Official Regulatory Statement
Documented Presentations	Overdosage is primarily characterized by severe diarrhea and abdominal cramps (signs of overdosage). Other documented presentations include nausea, vomiting, headache, dizziness, and certain CNS effects.
Severe Outcomes	The chief severe outcome is severe fluid loss leading to potentially life-threatening electrolyte disturbances, specifically hypokalemia (low potassium) and hypernatremia (high sodium). The labeling also notes potential for liver toxicity at elevated exposures.
Mandated Actions	Upon suspected overdose, individuals must contact a poison control center or emergency room at once. Seek emergency medical attention is required even if initial symptoms are not immediately present.

Evict